The First mRNA Cancer Vaccine Just Cleared a Phase 3 Trial

Cancer vaccines have a long, discouraging history: a genuinely promising idea that has failed, again and again, the moment it reached a large randomized trial. On August 19, 2026, that streak broke. Merck and Moderna announced that INTerpath-001, a Phase 3 trial of their personalized mRNA melanoma vaccine, met both of its primary endpoints — the first time a neoantigen cancer vaccine has succeeded in a randomized, late-stage study of this kind.

What actually got tested

The vaccine, called intismeran autogene (also known by its earlier names mRNA-4157 and V940), isn't off-the-shelf. Each dose is manufactured individually: a patient's tumor is sequenced, an algorithm predicts which mutated proteins (neoantigens) are most likely to trigger an immune response, and Moderna builds an mRNA vaccine encoding up to 34 of them, specific to that one patient's cancer. INTerpath-001 enrolled 1,137 patients with completely resected (surgically removed) stage IIB-IV melanoma, randomizing them 2:1 to receive the personalized vaccine alongside Merck's Keytruda (pembrolizumab), or Keytruda alone.

The result, and what's still missing

The trial met its primary endpoint, recurrence-free survival (RFS), and its key secondary endpoint, distant metastasis-free survival (DMFS), both improved with a statistically significant, "clinically meaningful" margin over Keytruda alone, according to the companies. What Merck and Moderna have not yet released is the actual numbers — the hazard ratios and percentage improvements that would let an oncologist size up exactly how much benefit this adds. That data is being saved for presentation at a subsequent medical meeting, which is common practice, but it does mean the current headline is real, and still incomplete.

The current headline is real, but incomplete — the actual hazard ratios are still being saved for a medical conference presentation.

Why the earlier data was already convincing

INTerpath-001 was closely watched because the smaller Phase 2b trial (KEYNOTE-942) that preceded it had already shown a large effect: a 49% reduction in the risk of recurrence or death, and a 59% reduction in the risk of distant metastasis or death, versus Keytruda alone. Those numbers held up at 3-year and even 5-year follow-up, which is unusually durable for an early-phase oncology result. Phase 3's job was simply to confirm that effect held at a much larger scale and wasn't a statistical fluke — and it did.

Why this is bigger than one drug

The significance goes beyond melanoma. Intismeran autogene is built on a general-purpose platform: sequence the tumor, predict the neoantigens, manufacture a personalized vaccine, repeat. Moderna and Merck are already running earlier-stage trials applying the same approach to lung cancer and other solid tumors. It's a different biotech strategy than the gene-editing work we've covered elsewhere, but part of the same broader shift toward medicine built around one patient's specific biology rather than a one-size-fits-all drug. A confirmed Phase 3 win in melanoma is the proof-of-concept the rest of that pipeline needed.

What happens next

Merck and Moderna say they'll present full trial data at an upcoming international medical meeting and begin engaging regulators on a filing for intismeran autogene plus Keytruda in resected melanoma. Overall survival — the gold-standard endpoint regulators and oncologists care about most — is still being tracked as a secondary endpoint and will take longer to read out. Until the full data set and a regulatory decision arrive, this is a confirmed, statistically significant win with the specifics still to come, not yet an approved treatment.